Brigitte Roos

1.7k total citations · 1 hit paper
18 papers, 1.4k citations indexed

About

Brigitte Roos is a scholar working on Dermatology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Brigitte Roos has authored 18 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Dermatology, 6 papers in Infectious Diseases and 6 papers in Molecular Biology. Recurrent topics in Brigitte Roos's work include Acne and Rosacea Treatments and Effects (5 papers), Retinoids in leukemia and cellular processes (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Brigitte Roos is often cited by papers focused on Acne and Rosacea Treatments and Effects (5 papers), Retinoids in leukemia and cellular processes (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Brigitte Roos collaborates with scholars based in Switzerland, United States and Hungary. Brigitte Roos's co-authors include E. Weidekamm, Masahiro Utoh, Ludger Banken, Bruno Reigner, Jim Cassidy, Anne Schmitt‐Hoffmann, Étienne Dumont, Sarah Durston, Kazushige Mori and M. Heep and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, International Journal of Antimicrobial Agents and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Brigitte Roos

18 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

2000 547 citations Jim Cassidy, Étienne Dumont et al. Cancer Chemotherapy and Pharmacology profile →

Peers

Countries citing papers authored by Brigitte Roos

Since Specialization

Citations

This map shows the geographic impact of Brigitte Roos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitte Roos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitte Roos more than expected).

Fields of papers citing papers by Brigitte Roos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitte Roos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitte Roos. The network helps show where Brigitte Roos may publish in the future.

Co-authorship network of co-authors of Brigitte Roos

This figure shows the co-authorship network connecting the top 25 collaborators of Brigitte Roos. A scholar is included among the top collaborators of Brigitte Roos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brigitte Roos. Brigitte Roos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Oral alitretinoin: a review of the clinical pharmacokinetics and pharmacodynamics 2012 ·Expert Review of Clinical Pharmacology ·(unknown), Brigitte Roos, Andreas Schoetzau, (unknown), Ingo Meyer, Jacqueline van de Wetering, Péter Kovács	7
2	Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid) 2011 ·Clinical and Experimental Dermatology ·Anne Schmitt‐Hoffmann, Brigitte Roos, (unknown), (unknown), Péter Kovács, K. Stoeckel, J. Maares	12
3	Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate 2011 ·Clinical and Experimental Dermatology ·(unknown), Brigitte Roos, (unknown), (unknown), Andreas Schoetzau, Philip T. Leese, E. Weidekamm, J. Maares	8
4	Pharmacokinetic interactions between alitretinoin and ketoconazole or simvastatin or ciclosporin A 2011 ·Clinical and Experimental Dermatology ·(unknown), Brigitte Roos, (unknown), Jochen Spickermann, J. Maares, Andreas Schoetzau, Ingo Meyer	14
5	Low levels of alitretinoin in seminal fluids after repeated oral doses in healthy men 2011 ·Clinical and Experimental Dermatology ·(unknown), Brigitte Roos, (unknown), Tom Brown, E. Weidekamm, Ingo Meyer, (unknown), J. Maares	11
6	Pharmacokinetics, efficacy and safety of alitretinoin in moderate or severe chronic hand eczema 2011 ·Clinical and Experimental Dermatology ·(unknown), Brigitte Roos, (unknown), Jochen Spickermann, K. Stoeckel, (unknown), Jacqueline van de Wetering, Pieter Jan Coenraads, J. Maares	14
7	Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557 2009 ·Antimicrobial Agents and Chemotherapy ·Anne Schmitt‐Hoffmann, Brigitte Roos, Jochen Spickermann, M. Heep, Eva Péterfai, David J. Edwards, K. Stoeckel	59
8	P1675 QTc measurements during a placebo- and actively controlled multiple dose study of two different dosing regimens of isavuconazole 2007 ·International Journal of Antimicrobial Agents ·M. Heep, Brigitte Roos, (unknown), Anne Schmitt‐Hoffmann, (unknown), (unknown), Guillaume Voiriot	2
9	P987 Steady-state bioavailability of oral isavuconazole in healthy volunteers 2007 ·International Journal of Antimicrobial Agents ·Anne Schmitt‐Hoffmann, Brigitte Roos, M. Heep	5
10	Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers 2005 ·Antimicrobial Agents and Chemotherapy ·Anne Schmitt‐Hoffmann, Brigitte Roos, J. Maares, M. Heep, (unknown), E. Weidekamm, Thomas A. Brown, (unknown)	117
11	Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers 2005 ·Antimicrobial Agents and Chemotherapy ·Anne Schmitt‐Hoffmann, Brigitte Roos, M. Heep, Michael Schleimer, E. Weidekamm, Thomas A. Brown, (unknown), Christoph Beglinger	139
12	Multiple-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers 2004 ·Antimicrobial Agents and Chemotherapy ·Anne Schmitt‐Hoffmann, (unknown), Brigitte Roos, Michael Schleimer, (unknown), (unknown), Tom Brown, Anthony Man, E. Weidekamm	70
13	Single-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers 2004 ·Antimicrobial Agents and Chemotherapy ·Anne Schmitt‐Hoffmann, Brigitte Roos, Michael Schleimer, (unknown), Anthony Man, (unknown), Tom Brown, (unknown), E. Weidekamm, Péter Kovács	87
14	Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients breakdown → 2000 ·Cancer Chemotherapy and Pharmacology ·(unknown), Jim Cassidy, Étienne Dumont, Brigitte Roos, Ludger Banken, Kazushige Mori, Bruno Reigner, Masahiro Utoh, E. Weidekamm, Sarah Durston	547
15	Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients 1999 ·Cancer Chemotherapy and Pharmacology ·Jim Cassidy, Chris Twelves, David Cameron, William P. Steward, Kenneth J. O’Byrne, Duncan I. Jodrell, Ludger Banken, Timothy Goggin, David C. Jones, Brigitte Roos, Ernie D. Bush, E. Weidekamm, Bruno Reigner	2
16	Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. 1999 ·PubMed ·Chris Twelves, Rob Glynne‐Jones, Jim Cassidy, J. Schüller, Timothy Goggin, Brigitte Roos, Ludger Banken, Masahiro Utoh, E. Weidekamm, Bruno Reigner	123
17	Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients 1999 ·Cancer Chemotherapy and Pharmacology ·Bruno Reigner, (unknown), Jim Cassidy, Duncan I. Jodrell, Rainer Schulz, Timothy Goggin, Ludger Banken, Brigitte Roos, Masahiro Utoh, Thomas Mulligan, E. Weidekamm	62
18	Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. 1998 ·PubMed ·Bruno Reigner, Jaco J. Verweij, Luc Dirix, Jim Cassidy, Chris Twelves, David Allman, E. Weidekamm, Brigitte Roos, Ludger Banken, Masahiro Utoh, B Osterwalder	139

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact